Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

16.07 +0.06 (+0.37%)
Delayed Quote Updated: 4:00 PM EST, Nov 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,325,959
Open 16.05
Bid (Size) 15.80 (200)
Ask (Size) 16.27 (200)
Prev. Close 16.01
Today's Range 15.70 - 16.23
52wk Range 14.68 - 24.68
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance ↗
Sarepta Therapeutics (NASDAQ:SRPT) expects updates from its experimental neuromuscular disease programs to help shape its next phase of growth, while relying on its Duchenne muscular dystrophy business... 
Via MarketBeat
News headline image
Sarepta (SRPT) Q3 2026 Earnings Call Transcript ↗
Gene therapy demand stabilizes while siRNA readouts and FDA talks loom ahead. 
Via The Motley Fool
Topics Earnings

Performance

52-Week Range 34.9% below 52-week high
16.07
14.6852W Low 24.6852W High
1 Week 11.0% below 1-week high
15.701W Low 18.051W High

Sarepta Therapeutics, Inc. - Common Stock (SRPT) traded between $14.68 and $24.68 over the past 52 weeks and last traded at $16.07, 34.9% below its 52-week high. Over the past week it ranged between $15.70 and $18.05.

Past 12 Months
-6.8%
-4.5%
-11.2%
-8.4%
-24.6%
-9.8%
1W -$1.17
1M -$0.76
3M -$2.03
6M -$1.48
YTD -$5.24
1Y -$1.75

SRPT was -9.8% over the past year, -8.4% over six months, -24.6% year to date, -6.8% in the last week.

12 Months vs Market
SRPT
-9.8%
DIA
+10.2%
SPY
+12.3%
QQQ
+11.8%
IWM
+17.2%

Over the past 12 months SRPT returned -9.8% versus DIA (Dow) +10.2%, SPY (S&P 500) +12.3%, QQQ (Nasdaq 100) +11.8% and IWM (Russell 2000) +17.2%.

Volume & Liquidity 0.49× 3-mo avg
Today 1,325,959 3-mo avg 2.7M
1W
2.3M
1M
2.4M
3M
2.7M
6M
3.0M
YTD
3.0M
1Y
3.0M

SRPT most recently traded 1,325,959 shares against a 3-month average daily volume of 2.7M.

More News

Read More
News headline image
Sarepta Therapeutics Q3 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Sarepta Therapeutics (NASDAQ:SRPT) Q3 2026 Beat Fails to Lift Shares as Pipeline Readouts Loom ↗
Via Chartmill
Sarepta Therapeutics (NASDAQ:SRPT) Surges on Q2 Earnings Beat and Narrowed Outlook ↗
Via Chartmill
Topics Earnings
News headline image
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near ↗
Via MarketBeat
News headline image
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Sarepta (SRPT) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Sarepta Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
Via The Motley Fool
Topics Artificial Intelligence

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 16.07
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 11/13/26 04:00 PM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.50B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.